MedPAC called for changes to Medicare Part D to remove the financial disincentives that block the use of lower-cost biosimilar therapies.
The Medicare Payment Advisory Commission (MedPAC), an independent congressional agency that advises Congress on issues affecting the Medicare program, provided a status report on Medicare Part D during a public meeting on January 11, 2018. MedPAC called for changes to Part D to remove the financial disincentives that block the use of lower-cost biosimilar therapies.
According to the report, the Medicare Part D program had nearly $80 billion in spending in 2016, with $79 billion spent on payments to Part D plans and $1 billion spent on the retiree drug subsidy. Plan enrollees paid approximately $13 billion in premiums (excluding premium subsidies for low-income enrollees), plus additional amounts in cost-sharing.
The status report notes that, while high-cost enrollees (those who have reached the catastrophic phase) were only 8% of Part D enrollees in 2015, these enrollees accounted for 57% of overall spending. “Nearly all of the growth in spending for high-cost enrollees is due to higher prices,” notes the report, and the “use of higher-priced drugs will continue to put strong upward pressure on program spending.” This trend is likely to continue long-term because of the increased focus on specialty drugs—including costly biologic therapies—in drug developers’ pipelines.
Growth in Part D enrollment, says the report, especially among non—low-income-subsidy (non-LIS) enrollees, has driven more catastrophic spending; enrollment in the Part D program has grown approximately 6% per year since 2007, reaching 42.5 million enrollees in 2017. Also driving up spending are the coverage gap discount, plan incentives to put high-price and high-rebate drugs on formularies, and higher drug prices overall.
MedPAC notes that high-cost biologics will only continue to grow in importance in the years ahead, increasing the cost burden on enrollees and on Medicare. Biosimilars, MedPAC says, are important tools that can to promote price competition.
However, some Part D policies, such as copays for LIS enrollees, are negatively affecting biosimilar uptake. MedPAC also notes that the coverage gap discount provides a financial advantage for originator biologics rather than for cheaper biosimilars, and calls for a removal of the financial disincentive for using lower-cost biosimilar options.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.